NASDAQ:ETNB 89bio (ETNB) Stock Price, News & Analysis → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Free ETNB Stock Alerts $11.47 +0.16 (+1.41%) (As of 12:09 PM ET) Add Compare Share Share Today's Range$11.01▼$11.5850-Day Range$8.13▼$13.7752-Week Range$6.57▼$22.93Volume204,642 shsAverage Volume1.36 million shsMarket Capitalization$1.07 billionP/E RatioN/ADividend YieldN/APrice Target$28.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get 89bio alerts: Email Address 89bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside154.9% Upside$28.83 Price TargetShort InterestBearish11.88% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 6 Articles This WeekInsider TradingAcquiring Shares$20.72 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.20) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.28 out of 5 starsMedical Sector545th out of 939 stocksPharmaceutical Preparations Industry254th out of 435 stocks 4.3 Analyst's Opinion Consensus Rating89bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.83, 89bio has a forecasted upside of 154.9% from its current price of $11.31.Amount of Analyst Coverage89bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.88% of the outstanding shares of 89bio have been sold short.Short Interest Ratio / Days to Cover89bio has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in 89bio has recently increased by 2.30%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend Yield89bio does not currently pay a dividend.Dividend Growth89bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ETNB. Previous Next 3.0 News and Social Media Coverage News Sentiment89bio has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for 89bio this week, compared to 3 articles on an average week.Search Interest13 people have searched for ETNB on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.MarketBeat Follows9 people have added 89bio to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 89bio insiders have bought 42,916.84% more of their company's stock than they have sold. Specifically, they have bought $20,722,500.00 in company stock and sold $48,173.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of 89bio is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 89bio are expected to decrease in the coming year, from ($2.20) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 89bio is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 89bio is -5.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio89bio has a P/B Ratio of 1.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> About 89bio Stock (NASDAQ:ETNB)89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Read More ETNB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETNB Stock News HeadlinesMarch 16, 2024 | insidertrades.com89bio, Inc. (NASDAQ:ETNB) Director Buys $20,722,500.00 in StockMarch 28, 2024 | americanbankingnews.com89bio (NASDAQ:ETNB) Given "Buy" Rating at HC WainwrightMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.March 27, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)March 27, 2024 | globenewswire.com89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated CirrhosisMarch 24, 2024 | americanbankingnews.com89bio (NASDAQ:ETNB) Stock Price Up 3.5%March 16, 2024 | finance.yahoo.comETNB Apr 2024 12.500 putMarch 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Intuitive Surgical (ISRG)March 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.March 12, 2024 | globenewswire.com89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with FibrosisMarch 10, 2024 | 247wallst.comBuffett Loads Up on This Stock Again, Plus CEO Insider BuyingMarch 8, 2024 | globenewswire.com89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 7, 2024 | msn.comInsider Trading: Director Boosts Stake in 89bio (NASDAQ:ETNB) StockMarch 7, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for 89bio with Potential Market Edge in Fibrosis and Metabolic DiseasesMarch 6, 2024 | realmoney.thestreet.com89bio price target raised by $8 at Evercore ISI, here's whyMarch 5, 2024 | globenewswire.com89bio to Participate in the Leerink Partners Global Biopharma ConferenceMarch 5, 2024 | wsj.com89bio Inc.March 5, 2024 | finance.yahoo.comETNB Mar 2024 20.000 putMarch 5, 2024 | finance.yahoo.comETNB Mar 2024 20.000 callMarch 2, 2024 | finance.yahoo.com89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ...February 29, 2024 | globenewswire.com89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdatesFebruary 24, 2024 | edition.cnn.com89bio IncFebruary 17, 2024 | ca.finance.yahoo.comETNB Mar 2024 15.000 callFebruary 17, 2024 | finance.yahoo.comETNB Mar 2024 7.500 putFebruary 6, 2024 | finance.yahoo.com89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 6, 2024 | finanznachrichten.de89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 6, 2024 | msn.comEli Lilly hurts NASH drug developers after mid-stage win for obesity therapySee More Headlines Receive ETNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ETNB CUSIPN/A CIK1785173 Webwww.89bio.com Phone415-432-9270FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$28.83 High Stock Price Target$37.00 Low Stock Price Target$14.00 Potential Upside/Downside+154.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-142,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-31.01% Return on Assets-27.84% Debt Debt-to-Equity Ratio0.05 Current Ratio20.04 Quick Ratio20.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.75 per share Price / Book1.97Miscellaneous Outstanding Shares93,501,000Free Float89,387,000Market Cap$1.06 billion OptionableOptionable Beta1.04 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Rohan Palekar (Age 58)CEO & Director Comp: $990.52kMr. Quoc Le-Nguyen (Age 56)Chief Technical Operations Officer & Head of Quality Comp: $654.44kDr. Harry Mansbach M.D. (Age 59)Chief Medical Officer Comp: $691.87kMr. Ryan Stephen Martins (Age 45)Chief Financial Officer Mr. Shiva K. Natarajan C.P.A. (Age 58)Senior Vice President of Finance & Principal Accounting Officer Ms. Annie J. Chang M.B.A.VP of Investor Relations & Corporate CommunicationsMs. Amanda KuriharaVice President of People & CultureMs. Yun Bai Ph.D.VP and Head of Chemistry, Manufacturing & Controls ( CMC )Ms. Melissa AbelSenior Vice President of Commercial StrategyMr. Paul ShinSenior Vice President of R&D OperationsMore ExecutivesKey CompetitorsCentessa PharmaceuticalsNASDAQ:CNTAVerve TherapeuticsNASDAQ:VERVZentalis PharmaceuticalsNASDAQ:ZNTLSage TherapeuticsNASDAQ:SAGEARS PharmaceuticalsNASDAQ:SPRYView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Bought 82,000 shares on 3/27/2024Ownership: 0.088%PNC Financial Services Group Inc.Bought 1,360 shares on 3/22/2024Ownership: 0.016%Vanguard Group Inc.Bought 781,803 shares on 3/11/2024Ownership: 4.607%Wellington Management Group LLPBought 239,027 shares on 3/5/2024Ownership: 0.256%Ra Capital Management, L.P.Bought 1,350,000 shares on 3/4/2024Total: $20.72 M ($15.35/share)View All Insider TransactionsView All Institutional Transactions ETNB Stock Analysis - Frequently Asked Questions Should I buy or sell 89bio stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ETNB shares. View ETNB analyst ratings or view top-rated stocks. What is 89bio's stock price target for 2024? 6 brokers have issued 12 month target prices for 89bio's stock. Their ETNB share price targets range from $14.00 to $37.00. On average, they anticipate the company's share price to reach $28.83 in the next twelve months. This suggests a possible upside of 154.9% from the stock's current price. View analysts price targets for ETNB or view top-rated stocks among Wall Street analysts. How have ETNB shares performed in 2024? 89bio's stock was trading at $11.17 at the start of the year. Since then, ETNB shares have increased by 1.3% and is now trading at $11.31. View the best growth stocks for 2024 here. When is 89bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ETNB earnings forecast. How were 89bio's earnings last quarter? 89bio, Inc. (NASDAQ:ETNB) posted its earnings results on Thursday, February, 29th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.01. What ETFs hold 89bio's stock? ETFs with the largest weight of 89bio (NASDAQ:ETNB) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Invesco DWA SmallCap Momentum ETF (DWAS), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC) and Harbor Health Care ETF (MEDI).iShares Micro-Cap ETF (IWC). What other stocks do shareholders of 89bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), RTX (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO). When did 89bio IPO? 89bio (ETNB) raised $70 million in an IPO on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager. Who are 89bio's major shareholders? 89bio's stock is owned by a number of institutional and retail investors. Top institutional investors include RTW Investments LP (5.99%), Vanguard Group Inc. (4.62%), Vanguard Group Inc. (4.61%), BVF Inc. IL (4.34%), Frazier Life Sciences Management L.P. (2.15%) and Federated Hermes Inc. (2.11%). Insiders that own company stock include Edward Morrow Atkinson III, Gregory Grunberg, Kathleen Laporte, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins. View institutional ownership trends. How do I buy shares of 89bio? Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ETNB) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.